Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Public ClinicalTrials.gov record NCT02135445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Study identification
- NCT ID
- NCT02135445
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- TAK-385 Drug
- Degarelix Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014
- Primary completion
- Nov 30, 2015
- Completion
- Nov 30, 2015
- Last update posted
- Apr 12, 2017
2014 – 2015
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Daytona Beach | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Jeffersonville | Indiana | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Virginia Beach | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02135445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02135445 live on ClinicalTrials.gov.